Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T67363
|
||||
| Former ID |
TTDI01789
|
||||
| Target Name |
Integrin alpha-5/beta-3
|
||||
| Gene Name |
ITGB3
|
||||
| Synonyms |
ITGB3
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Renal cancer [ICD9: 140-229, 189; ICD10: C64] | ||||
| Function |
Integrin alpha-5/beta-1 is a receptor for fibronectin and fibrinogen. It recognizes the sequence R-G-D in its ligands. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
|
||||
| BioChemical Class |
Integrin
|
||||
| UniProt ID | |||||
| Sequence |
MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLG
SPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRP DDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFG AFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSR NRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCH VGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLS MDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDT VSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGT FECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFG KITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLL CSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRY CRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDIL VVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTF TNITYRGT |
||||
| Structure |
3VI3; 3VI4; 4WJK; 4WK0; 4WK2; 4WK4
|
||||
| Drugs and Mode of Action | |||||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| KEGG Pathway | Phagosome | ||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| ECM-receptor interaction | |||||
| Hematopoietic cell lineage | |||||
| Regulation of actin cytoskeleton | |||||
| Bacterial invasion of epithelial cells | |||||
| Shigellosis | |||||
| Pertussis | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| Hypertrophic cardiomyopathy (HCM) | |||||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | |||||
| Dilated cardiomyopathy | |||||
| Reactome | Platelet degranulation | ||||
| Elastic fibre formation | |||||
| Fibronectin matrix formation | |||||
| PECAM1 interactions | |||||
| Molecules associated with elastic fibres | |||||
| Integrin cell surface interactions | |||||
| Syndecan interactions | |||||
| ECM proteoglycans | |||||
| Integrin alphaIIb beta3 signaling | |||||
| SOS provides linkage to MAPK signaling for Integrins | |||||
| p130Cas linkage to MAPK signaling for integrins | |||||
| VEGFA-VEGFR2 Pathway | |||||
| MAP2K and MAPK activation | |||||
| WikiPathways | Focal Adhesion | ||||
| Extracellular matrix organization | |||||
| Elastic fibre formation | |||||
| Arrhythmogenic Right Ventricular Cardiomyopathy | |||||
| Integrin-mediated Cell Adhesion | |||||
| L1CAM interactions | |||||
| Integrin cell surface interactions | |||||
| Cell surface interactions at the vascular wall | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.